


# AlphaDaRT

Revolutionary  
Alpha-Emitters Radiotherapy  
at



## Enrolling Recurrent Cutaneous Squamous Cell Carcinoma Patients

Alpha DaRT is the first localized anticancer therapy that utilizes alpha radiation for the treatment of solid tumors. It is designed to release short-lived alpha-emitting atoms in the tumor aiming to deliver a high but conformal dose of radiation inside the tumor while sparing surrounding healthy tissue.



**Targeted  
treatment**



**No systemic  
toxicity observed**



**Minimal local  
toxicity observed**



**Safe procedure for  
caregivers**



**No suppression of  
immune system observed**

Following FDA Breakthrough Device Designation for the treatment of cutaneous SCC, a 100% complete response rate was observed in our pilot feasibility study with the participation of University Cancer Center in Houston. Alpha Tau Medical is now actively recruiting patients with recurrent cutaneous SCC to our pivotal US trial that is open in select major medical centers across the U.S.

## Which patients are eligible for the trial\*

- **Recurrent non-metastatic cutaneous SCC patients with limited options:**
  - Who have failed at least first line standard of care therapy
  - With any skin lesions including:
    - Cheek (external)
    - Ear
    - Nose
    - Lip (external)
    - Forehead
    - Scalp
    - Limbs (including hands, feet)
    - Fingers
    - Chest
    - Neck

\*For complete eligibility criteria, please visit [clinicaltrials.gov](https://clinicaltrials.gov)